Cycle on Jun 5, 2026

I will start by listing the open threads and watches for this topic to understand what we are tracking and if any existing threads need resolution or if any watches have been triggered.

I will read the existing notes for this topic to understand what has been covered recently.

The current date is June 5, 2026. Let's do some web searches to look for major science/health events, drug approvals, disease outbreaks, space/biology/energy breakthroughs from the last few days (specifically June 3-5, 2026), or updates on existing topics. I'll search for: 1. WHO/CDC/outbreak updates (Ebola Bundibugyo, H5N1, etc.) 2. Drug approvals / clinical trials (especially ASCO 2026, which is taking place around now - ASCO usually runs late May to early June, let's see what is happening at ASCO 2026 or other health news) 3. Space/science/fusion breakthroughs. Let's do a web search with `sort="recent"` and `freshness="week"`. Let's search for "FDA approval", "outbreak", "clinical trial", "ASCO 2026", "Ebola", "H5N1", etc.

Okay, let's look at the results. We have: 1. "ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer..." (Akeso's ivonescimab, a bispecific antibody, made a historic ASCO Plenary debut showing a 34% lower death risk against a PD-1 inhibitor (Keytruda, pembrolizumab?) or chemotherapy? Let's check this). 2. "Innovent, fresh from $1.2B deal, posts key win for CLDN18.2 ADC" (IBI343, an antibody-drug conjugate targeting CLDN18.2, phase 3 victory). 3. "Grail Stock Surges Over 11 Percent Following Post-ASCO Share Dip" - "NHS Galleri trial missed primary endpoint but showed positive trends in deadly cancers." 4. Let's do some more target searches on specific science and health news from June 2026. For instance, what about "Ebola" or "H5N1" or other health updates? Let's search for "Ebola Bundibugyo" or "H5N1" to see if there are updates. Let's do a search.

Wow, this is an incredible, highly relevant, and major news update on the Bundibugyo Ebola outbreak! Let's see: "US adds $38 million for Ebola as CDC warns outbreak could match 2014" and "WHO and Africa CDC unveil $518m Ebola plan as DRC, Uganda death tolls rise" and "CDC report: Ebola outbreak could rival the worst on record unless world acts" all published today, June 5, 2026. Let's fetch these pages to get the exact details. First, let's fetch the CIDRAP article or Al Jazeera or NPR or CDC media release. Let's do a few fetches. Let's fetch: 1. `https://www.cidrap.umn.edu/ebola/who-africa-cdc-announce-joint-ebola-response-plan` 2. `https://www.aljazeera.com/news/2026/6/5/who-africa-cdc-unveil-518m-ebola-plan-as-uganda-death-toll-rises` 3. `https://www.npr.org/2026/06/05/nx-s1-5848082/ebola-virus-cdc-outbreak-democratic-republic-congo-uganda` 4. `https://www.cdc.gov/media/releases/2026/update-on-ebola-outbreak-in-the-democratic-republic-of-the-congo-and-uganda-6-5-2026.html` Let's fetch the Al Jazeera article first.

Now let's fetch the NPR article on the CDC report and warning. It says: "CDC report: Ebola outbreak could rival the worst on record unless world acts". Let's fetch that.

Let's fetch the CDC's media release or a CIDRAP article to get more details on the $38 million US funding, the $518 million plan, and the specific papers published. Let's search for "CDC MMWR Ebola Bundibugyo June 5 2026" or similar to see what the three papers are about, or fetch the CIDRAP article. Let's fetch the CIDRAP article: `https://www.cidrap.umn.edu/ebola/who-africa-cdc-announce-joint-ebola-response-plan` Let's fetch it.

This is extremely clear and gives us the exact numbers: - 381 confirmed cases and 62 confirmed deaths in the DRC, with 16 confirmed cases and one death in Uganda. - Overall case-fatality rate is 15.9%, but more than 250 suspected deaths. - The outbreak is the fourth-largest outbreak overall and the largest caused by the Bundibugyo virus. - Joint plan by WHO and Africa CDC aims to raise $518 million over 6 months (June to November 2026). - US CDC published 3 MMWR papers on June 5, 2026. Under a scenario where only 20% of infected people are detected and isolated within two days of symptom onset, the outbreak could exceed 20,000 cases and 4,000 deaths by mid-August (within the next 3 months). - The US government announced on June 5, 2026, that it would provide an additional $38 million for the Ebola response. - Protests in Nanyuki, Kenya, close to Laikipia Air Base, on Monday and Tuesday (June 1-2, 2026) over a planned US Ebola quarantine facility (at least two people killed and one injured when demonstrations turned violent). This is a massive update to the existing note `bundibugyo-ebola-outbreak-drc-uganda`. Let's refine that note using that slug! First, let's also research the other topics that came up from our search. We had: 1. Akeso's ivonescimab (AK112) bests PD-1 inhibitor (Keytruda/pembrolizumab) in squamous/non-squamous NSCLC (lung cancer) at ASCO 2026. It made a historic ASCO Plenary debut. Let's search for "ivonescimab ASCO 2026" or "ivonescimab vs pembrolizumab" or "pembrolizumab ivonescimab lung cancer ASCO 2026" to get the exact details. This seems like a major drug trial readout at ASCO 2026! Let's search.

Let's fetch the Fierce Pharma article "ASCO: Akeso's ivonescimab bests PD-1 inhibitor in lung cancer..." or the ASCO Post article "Overall Survival Benefit With Ivonescimab Plus Chemotherapy in Advanced Squamous NSCLC" or the ASCO Daily News article "HARMONi-6: Ivonescimab + Chemo Improves OS Versus...". Let's fetch `https://www.fiercepharma.com/pharma/asco-akeso-ivonescimab-bests-pd-1-inhibitor-squamous-nsclc-overall-survival` to understand the details.

This is a fantastic and extremely detailed source for ivonescimab (AK112). Let's summarize the key findings from this paper and our search: - **Drug**: Ivonescimab (AK112), a first-in-class PD-1xVEGF bispecific antibody, developed by Akeso (and licensed to Summit Therapeutics). - **Trial**: Phase 3 **Harmoni-6** (AK112-306) trial conducted in China. It's the first time a China-only dataset was selected for presentation at the prestigious plenary session of the American Society of Clinical Oncology (ASCO 2026). - **Comparator**: Ivonescimab + chemotherapy versus tislelizumab (Tevimbra, an anti-PD-1 by BeOne Medicines / BeiGene) + chemotherapy. - **Indication**: Previously untreated (first-line), advanced squamous non-small cell lung cancer (NSCLC). - **Primary/Key Results**: - Slashed the risk of death by **34%** (Overall Survival Hazard Ratio = 0.66, p-value = 0.0017, meeting the prespecified statistical boundary of 0.0049). - Improved median overall survival (OS) by **4.2 months** compared to tislelizumab + chemo, reaching **27.9 months** vs **23.7 months** for the control group. - Median follow-up was 21.4 months. - OS benefit was consistent between PD-L1-negative (36% improvement) and PD-L1-positive (32% improvement) patients. - Grade 3 or above hemorrhages occurred in 2.6% of patients in the ivonescimab-chemo group vs 0.8% in the control group (historically, separate VEGF inhibitors like bevacizumab were prohibited in squamous NSCLC due to severe bleeding risks, so this is a notable safety win). - **Caveats / Critiques**: - Discussant Dr. Julie Brahmer (Johns Hopkins) called the results "provocative" rather than practice-changing for the global population. - Applicability to global populations is questioned: Almost exclusively conducted in men; excluded patients over 75 years of age. - In patients aged 65 and above, ivonescimab + chemo showed no benefit (hazard ratio nearly 1), which mirrors historical data with VEGF inhibitor bevacizumab in elderly patients. - Short follow-up: Median follow-up (21.4 months) is shorter than the median OS of both arms. This is a major finding for ASCO 2026 and oncology! Let's write a dedicated note for this. Let's do some more web searches to see what else has happened in the last few days in science/health. For instance, was there another big ASCO trial? - Innovent's CLDN18.2 ADC trial win? - Let's check Grail's Galleri trial: "NHS Galleri trial missed primary endpoint but showed positive trends in deadly cancers." Let's do a search on Grail's Galleri trial results from June 2026. This is a massive multi-cancer early detection test! Let's see what the results were.

Let's fetch the STAT News article about Grail's trial results: `https://www.statnews.com/2026/06/04/grail-multi-cancer-early-detection-test-trial-results/` (or the Science Media Centre expert reaction page, or Medtech Dive). Let's fetch the STAT News article first. If it has a paywall, we can try another. Let's try fetching the STAT News article.

Ah, the fetch returned the first few paragraphs. Let's fetch another source to get the full story of the results, such as the Science Media Centre expert reaction page `https://www.sciencemediacentre.org/expert-reaction-to-press-release-from-grail-on-full-results-of-the-nhs-galleri-trial-being-presented-at-asco/` or Medtech Dive `https://www.medtechdive.com/news/at-asco-grail-points-to-positive-signals-in-mced-data/821736/`. Let's fetch the Science Media Centre page.

This is an extremely detailed and thorough source! Let's synthesize the Grail NHS-Galleri trial results: - **Test**: Grail's Galleri, a multi-cancer early detection (MCED) blood test. It detects epigenetic patterns (methylation) in circulating cell-free DNA (cfDNA) in the blood. - **Trial**: NHS-Galleri trial, the world's first large-scale randomized controlled trial of an MCED test. It randomized 143,000 average English adults aged 50–77 to either usual care or MCED testing. - **Presentation**: Presented by Charles Swanton (Francis Crick Institute) at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting. - **Primary Endpoint**: Reduction in combined stage III and IV (late-stage) cancers across all cancer types after three rounds of annual screening over 3 years. - **Key Outcome**: **The trial missed its primary endpoint.** The combined rate of stage III and IV cancer diagnoses did not significantly decrease overall across the 3-year study period. - **Why it missed / Nuances**: - In the first (prevalent) screening round, there was a "bump" in cancer detection, particularly finding many stage III cancers (which may have been asymptomatic cases that would have otherwise progressed or been diagnosed later). This increase in stage III diagnoses in the first round offset any reduction and caused the primary endpoint to fail. - **Secondary / Positive Findings**: - **Stage IV Reduction**: There was a substantial and strengthening reduction specifically in **Stage IV** cancer diagnoses (the most advanced and lethal) as the trial progressed, reaching a **26% reduction** by the third screening round. - **For 12 Pre-specified Cancers**: There was a shift towards detecting cancers at earlier stages (stages I and II). - **Specificity**: The test maintained an impressively high specificity of **99.55%** and a positive predictive value (PPV) of **52.0%**, meaning very few false positives (more than half of those who had a positive blood test were indeed diagnosed with cancer). - **Cancer Signal of Origin (CSO)**: The test's accuracy in predicting where the cancer originated in the body was **92.5%**. - **Episode Sensitivity**: The test detected 30.7% of all cancers, and 54.7% of cancers in the pre-specified group of 12 cancers within 12 months after the blood test. - **Expert Critiques / Policy Implications**: - Prof Richard Houlston (Institute of Cancer Research, London) noted that Grail's press release presented findings far more positively than the overall results justified, leading with secondary endpoints while the primary endpoint failed. - Several confidence intervals for the Stage IV reduction crossed 1.0, making the results statistically uncertain. - Implementing Galleri at a population scale is not currently justified based on these results. It would place massive pressure on already stretched NHS diagnostic services (e.g., CT scans, biopsies) for asymptomatic patients at a time when the NHS is struggling to meet waiting-time targets. - Longer follow-up and mortality data (expected in a couple of years) will be crucial to determine if the test actually saves lives. This is a beautiful, highly nuanced, and major health/science story. It fits perfectly as a distinct finding for our topic. Let's do some more search for other major science/health news. Is there any other big news from the last few days? - "Innovent, fresh from $1.2B deal, posts key win for CLDN18.2 ADC" (IBI343, an antibody-drug conjugate). Let's search for "IBI343 Innovent ASCO 2026" or "IBI343 phase 3". - "Biogen's Salanersen Receives FDA Breakthrough Therapy Designation for Spinal Muscular Atrophy" (this was already covered in a prior cycle, slug: `salanersen-fda-breakthrough-spinal-muscular-atrophy`). - "Daraxonrasib Doubles Overall Survival in Advanced Pancreatic Cancer at ASCO 2026" (this was already covered in a prior cycle, slug: `daraxonrasib-pancreatic-cancer-survival-doubled`). - "Nuclear Fusion: Xcimer Energy Launches 'Phoenix,' World's Largest Private Laser System" (already covered, slug: `xcimer-phoenix-fusion-laser-launch`). - "Epidemiological Milestone: First Documented Cat-to-Human H5N1 Bird Flu Transmission" (already covered, slug: `first-cat-to-human-h5n1-transmission`). - Any new H5N1 updates? Or other disease outbreaks? Let's search for "H5N1" or "avian influenza" or "bird flu" from the last 3-4 days (June 2-5, 2026) to see if there is any major development. Let's do a search.

Wow, there are more updates here: 1. "mRNA bird flu vaccine hits late-stage testing" - let's search for "mRNA bird flu vaccine late-stage testing" or "GSK" or "Moderna" or "CSL" bird flu vaccine June 2026. 2. "France confirms hantavirus in cruise outbreak is not new or more transmissible" (cruise outbreak of hantavirus, Andes strain of virus from MV Hondius outbreak matches known South American strains). Let's search for "hantavirus cruise outbreak MV Hondius" to see if there's a major story there. 3. "Moderna joins race for Ebola vaccine as Bundibugyo strain spreads in Africa" / "Moderna gets $50M to work on Ebola vaccine". Let's search for "Moderna Ebola vaccine Bundibugyo June 2026". Let's do a search on: `"Moderna" Ebola vaccine Bundibugyo` OR `mRNA bird flu vaccine late-stage testing` OR `hantavirus cruise MV Hondius` OR `"Hondius" hantavirus` Let's see what comes up.

Let's fetch the BizJournals article or AOL article about Moderna getting $50M for the Bundibugyo Ebola vaccine. Let's fetch the AOL article: `https://www.aol.com/articles/moderna-gets-50m-investment-ebola-184828000.html`. Wait, let's also search for "CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates" to see what the other candidates are. Let's do a search on `CEPI fast-tracks three Bundibugyo ebolavirus vaccine candidates`. This will give us excellent context.

This is an excellent development! We have a second major angle for the Bundibugyo Ebola outbreak to include in our update, or we can write a detailed update note that covers the rapid expansion of the outbreak, the CDC's worst-case modeling, the WHO/Africa CDC response plan, and the fast-tracking of three vaccine candidates by CEPI (including Moderna, IAVI, and Oxford). Let's fetch the CIDRAP article about the CEPI fast-tracking: `https://www.cidrap.umn.edu/ebola/three-ebola-vaccine-candidates-fast-tracked-african-outbreak-continues`. Let's do that to get the precise details.

This is an outstanding resource! Let's examine the details: - **CEPI Funding**: CEPI is investing over $60 million (including up to $50 million for Moderna's mRNA vaccine, up to $3.2 million for IAVI's rVSV vaccine, and up to $8.6 million for the University of Oxford's ChAdOx1 vaccine) to fast-track three investigational vaccine candidates against the Bundibugyo ebolavirus. - **Outbreak Numbers**: - As of June 5, 2026, the official count stands at 381 confirmed cases and 62 confirmed deaths in the DRC, and 16 confirmed cases and 1 death in Uganda (CFR ~15.9%). However, there are more than 250 suspected deaths, and the true scale of the outbreak is unknown because of testing backlogs, conflict, and healthcare access issues (with MSF saying "nobody knows the true scale and severity of this outbreak"). - **US Quarantine Facility in Kenya**: - The US is building a quarantine facility on the Laikipia Air Base in Kenya for up to 50 Americans exposed to Ebola, which has sparked massive local protests in Nanyuki. Local citizens fear the facility will expose them to the virus and collapse their healthcare infrastructure. A Kenyan judge had blocked the construction, but the Kenyan federal government is moving forward with it. Protests turned violent, with at least two people killed and one injured on Monday, June 1, 2026. This is a comprehensive and highly significant update on the Bundibugyo Ebola outbreak. We should write a major update note using the existing slug `bundibugyo-ebola-outbreak-drc-uganda` to refine the prior finding. Let's do some more search on: - "France confirms hantavirus in cruise outbreak is not new or more transmissible" Let's see if there is a major story there. Let's do a search.

Let's read more about this MV Hondius hantavirus cruise ship outbreak. Let's see: - "France confirms hantavirus in cruise outbreak is not new or more transmissible" - "The regional Government of Spain's Canary Islands has opposed permitting the cruise ship contaminated by an outbreak of the deadly hantavirus to dock..." - "Five U.S. residents who were on the hantavirus-hit MV Hondius cruise ship have returned to their home states following three weeks of monitoring..." - "US cruise passenger quarantining for hantavirus says he will remain..." - "The MV Hondius cruise ship at the centre of the hantavirus outbreak has been cleared to resume operations after a multi-day disinfection effort." Wait! Let's check the date of the articles. Some of these are dated June 1, 2026, or June 2, 2026. Let's fetch the USA Today article "Cruise ship tied to hantavirus cleared to sail: Where it's headed" (June 1, 2026) or the Outside Online article "I Was on the Deadly Hantavirus Cruise. Now I'm One of 18 People in Quarantine." (published June 5, 2026). Let's fetch the Outside Online article to see what is going on.

This is a fascinating personal account of the MV Hondius Andes hantavirus cruise ship outbreak! Let's see: - On May 2, 2026, passengers aboard the MV Hondius (a 353-foot polar expedition cruise ship) experienced severe respiratory issues. - Three deaths in total were reported on the ship (by May 13, 2026). - The cause was confirmed to be the **Andes hantavirus** (specifically Andes virus, which is unique among hantaviruses for its ability to transmit person-to-person). - US passengers were evacuated and repatriated to the University of Nebraska Medical Center (UNMC) in Omaha, Nebraska, for a federally mandated 42-day quarantine (due to the virus's long incubation period). - As of June 5, 2026, passengers are 26 days into the 42-day quarantine, with 16 days remaining. Some passengers have been released to continue quarantining at home under monitoring. - The regional Government of Spain's Canary Islands originally rejected docking, but the ship eventually docked in Tenerife, Spain, where passengers were evacuated. - The Pasteur Institute confirmed that the Andes strain from the MV Hondius matches known South American strains and does not show signs of increased transmissibility or danger, but the person-to-person transmission potential of Andes virus necessitated strict federal quarantine. This is a very interesting, on-topic health story that is highly current (June 5, 2026). Let's write a distinct finding for this! Wait, let's look at another potential finding: "Innovent, fresh from $1.2B deal, posts key win for CLDN18.2 ADC" Let's search for "Innovent IBI343 ASCO 2026" or "IBI343 gastric cancer Phase 3" to see if this is highly significant. Let's do a search.

Excellent! Let's fetch the Fierce Biotech article: `https://www.fiercebiotech.com/biotech/innovent-fresh-12b-deal-posts-phase-3-win-cldn182-adc` to get all the details. This is another major clinical readout!

This is a great clinical readout! Let's summarize the key facts: - **Drug**: IBI343 (arcotatug tavatecan, TAK-921), an investigational antibody-drug conjugate (ADC) targeting Claudin-18.2 (CLDN18.2) with a cytotoxic exatecan (topoisomerase I inhibitor) payload. Developed by Innovent Biologics (Greater China rights) and partnered with Takeda (ex-China rights under a $1.2 billion deal signed in 2025). - **Indication**: Locally advanced unresectable or metastatic CLDN18.2-positive gastric or gastroesophageal junction (GEJ) adenocarcinoma. Patients had received at least two prior systemic lines of therapy. - **Trial**: International Phase 3 **MarsLight-11** (NCT06238843) study enrolling 464 patients in China and Japan. - **Results**: At the first pre-specified interim analysis, IBI343 met its primary endpoint of progression-free survival (PFS), demonstrating a statistically significant and clinically meaningful improvement compared to investigator-selected chemotherapy. - **Significance**: - This is the **world's first CLDN18.2-targeted ADC** to achieve a Phase 3 victory and enter regulatory review. - China's National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for IBI343 under priority review. - Astellas won FDA approval for an anti-CLDN18.2 monoclonal antibody (Vyloy/zolbetuximab) in 2024, but IBI343 represents a novel, more potent ADC modality. - Efficacy is described as "excellent" and safety as "good" with low rates of gastrointestinal-related toxicities. (Detailed numbers are being held for upcoming scientific conferences/journals). This is a beautiful and highly consequential health/oncology story! It fits as another distinct finding. Let's review our findings to write: 1. **Finding 1 (Update to `bundibugyo-ebola-outbreak-drc-uganda`)**: Global Health Emergency: The Bundibugyo Ebola Outbreak in DRC and Uganda. - We will update the note with the latest June 5, 2026 data. - We will include the new CDC modeling warning of up to 20,000 cases and 4,000 deaths by mid-August if isolation is slow. - We will include the joint WHO and Africa CDC $518 million response plan. - We will include the US government adding $38 million to the response. - We will include CEPI fast-tracking three vaccine candidates (Moderna's mRNA, Oxford's ChAdOx1, and IAVI's rVSV) with over $60 million in funding. - We will include the violent protests and deaths in Nanyuki, Kenya, over the planned US Ebola quarantine facility at Laikipia Air Base. 2. **Finding 2 (New finding: `ivonescimab-harmoni-6-lung-cancer-os-win`)**: Ivonescimab (AK112) Slashes Death Risk by 34% in Advanced Squamous Lung Cancer at ASCO 2026. - This covers the Phase 3 Harmoni-6 trial results. - It will cite Fierce Pharma, including the 34% reduction in risk of death, 4.2-month median OS improvement (27.9 vs 23.7 months), safety wins, and the important caveats (conducted in China, mostly men, excluded patients over 75, no benefit in patients over 65). 3. **Finding 3 (New finding: `grail-nhs-galleri-mced-trial-results`)**: Grail’s Galleri Multi-Cancer Blood Test Misses Primary Endpoint in Landmark NHS Trial. - This covers the full results of the NHS-Galleri trial presented at ASCO 2026. - It will cite the Science Media Centre expert reaction and STAT News. - It will explain the primary endpoint failure (reducing stage III and IV cancers over 3 years) due to a first-round detection "bump". - It will highlight the secondary findings: 26% reduction in Stage IV cancers by the third round, 99.55% specificity, 52% PPV, and 92.5% CSO accuracy. - It will discuss the expert critiques on the clinical utility, cost-effectiveness, and potential strain on NHS diagnostic resources. 4. **Finding 4 (New finding: `innovent-cldn182-adc-gastric-cancer-phase3`)**: World’s First CLDN18.2 ADC Submits NDA Following Phase 3 Gastric Cancer Win. - This covers Innovent's IBI343 (arcotatug tavatecan) Phase 3 win and NDA acceptance. - It will cite Fierce Biotech and explain the drug's mechanism, the MarsLight-11 trial, the Takeda partnership, and its significance as the first CLDN18.2 ADC to achieve regulatory review. Wait, are there any other threads or watches we should register? Let's see if there are any upcoming catalysts. For example, we should register a watch for: - The release of mortality data and peer-reviewed publication of the NHS-Galleri trial (expected in a couple of years, but we can set a tripwire or ongoing watch). - The FDA review or global Phase 3 trials of ivonescimab (HARMONi studies, including HARMONi-3 or HARMONi-7). - The regulatory decision on IBI343 in China (priority review accepted) and the readout of overall survival or global trials. - The clinical trials of the three fast-tracked Bundibugyo Ebola vaccines (Moderna, Oxford, IAVI). Let's check the guidelines: - "Every substantive finding MUST cite at least one real source you actually consulted THIS cycle — a web page you fetched, an HN story or comment you read, etc. Do NOT write notes from prior knowledge, training data, or memory." (We fetched all the pages we are citing!) - "LIFT THE EVIDENCE FORWARD. A finding that summarizes a discussion without quoting it or linking the actual source it's about is incomplete — go get the quote and the link before you write it." - "One finding = ONE thing that's happening (a single story, article, paper, launch, or debate). NEVER write a note that summarizes the cycle, bundles several themes or stories into one write-up, or is titled by date" (We are writing four distinct notes, one for each specific story!) - "To link ANOTHER finding from a note body, write its slug as a wikilink — `[[its-slug]]` (e.g. `[[apple-m5-mie-bypass-exploit]]`)." (We will link the updated Ebola note or use wikilinks where appropriate). Let's write the first note, which is the update to `bundibugyo-ebola-outbreak-drc-uganda`. Wait, let's look at the existing note's structure. The slug is `bundibugyo-ebola-outbreak-drc-uganda`. Let's draft the body of the note: We will include the latest numbers as of June 5, 2026: 381 confirmed cases / 62 confirmed deaths in DRC, 16 confirmed cases / 1 death in Uganda. Then the CDC modeling warning of up to 20,000 cases and 4,000 deaths by mid-August if isolation is slow. The WHO and Africa CDC joint plan raising $518 million over 6 months. The US contributing $38 million. CEPI committing over $60 million to fast-track three vaccines (Moderna, Oxford, IAVI). The violent protests in Nanyuki, Kenya, over the US Ebola quarantine facility at Laikipia Air Base. Let's write the updated note for `bundibugyo-ebola-outbreak-drc-uganda`. Let's perform the write_note call.

That is updated beautifully. Now, let's write the second note about ivonescimab (AK112) and the Phase 3 Harmoni-6 trial results presented at ASCO 2026. Let's select the slug: `ivonescimab-harmoni-6-lung-cancer-os-win`. Wait! The note body should start with the title as the first `# ` heading, and we should provide concrete quotes and links. Let's call `write_note` for ivonescimab.

Excellent. Now let's write the third note about the Grail NHS-Galleri MCED trial results presented at ASCO 2026. Let's select the slug: `grail-nhs-galleri-mced-trial-results`. Let's call `write_note` for this.

Superb. Now let's write the fourth note about Innovent's CLDN18.2 ADC Phase 3 win and NDA acceptance. Let's select the slug: `innovent-cldn182-adc-gastric-cancer-phase3`. Let's call `write_note` for this.

This is excellent. We have written four notes: 1. Updated `bundibugyo-ebola-outbreak-drc-uganda` 2. Created `ivonescimab-harmoni-6-lung-cancer-os-win` 3. Created `grail-nhs-galleri-mced-trial-results` 4. Created `innovent-cldn182-adc-gastric-cancer-phase3` Let's register some forward-looking watches using `record_watch`. Let's see: 1. For the Bundibugyo Ebola vaccine candidates fast-tracked by CEPI (Moderna, Oxford, IAVI), let's watch for Phase 1 clinical trial readouts or initiation of clinical trials in the affected countries. - Watch type: `live_process` or `tripwire` or `thesis_breaker`. Let's use `live_process` or `dated_catalyst`. Since we don't have a precise date for the trial readouts yet, let's use `ongoing` cardinality with a `live_process` watch type. 2. For the NHS-Galleri trial, let's watch for the release of the final overall mortality data, which is expected in the next few years (2028-2029). - Watch type: `live_process`, ongoing. 3. For ivonescimab (HARMONi studies), let's watch for the global Phase 3 HARMONi-3 or HARMONi-7 trial readouts to see if the overall survival benefit is replicated in a global population. - Watch type: `live_process`, ongoing. 4. For IBI343, let's watch for the Chinese NMPA's regulatory decision on its NDA (accepted for priority review in June 2026), which typically takes 6-9 months (late 2026 or early 2027). - Watch type: `scheduled_release` or `live_process`, ongoing or one-shot. Let's make it ongoing for NMPA regulatory approval of IBI343. Let's register these watches. Let's start with the Ebola vaccines.

Let's register a watch for the global HARMONi-3 and HARMONi-7 trials for ivonescimab (AK112). This will see if the 34% survival win in China is replicated globally.

Let's register a watch for the NMPA regulatory decision on IBI343 (arcotatug tavatecan) in China. It was accepted for priority review on June 4, 2026. This typically takes 6-12 months. Let's set a watch for late 2026 / early 2027. Let's make it a dated catalyst with a fire date of 2027-02-01T00:00:00Z.

Let's register a watch for the NHS-Galleri trial mortality data release. This is crucial for verifying if the test actually reduces cancer-specific mortality. It is expected in a couple of years. Let's make it an ongoing live process watch.

Excellent. We have registered our four forward-looking watches. Let's make sure we have everything resolved. We don't have any open threads to resolve, as `list_threads` returned an empty list. Let's call `finish_cycle` to complete this research cycle. This is the only way to end the cycle successfully.

I have completed the research cycle for topic `019e92c9-9dac-7a47-a1f2-f8f4037c94f9`! Here is a summary of what was accomplished in this cycle: 1. **Updated Finding (`bundibugyo-ebola-outbreak-drc-uganda`)**: * Refined the ongoing Bundibugyo Ebola outbreak note with crucial updates from June 5, 2026. This includes the latest confirmed figures (381 cases/62 deaths in the DRC, 16 cases/1 death in Uganda), the CDC's newly published modeling warning of a worst-case scenario exceeding 20,000 cases and 4,000 deaths by mid-August if isolation remains slow, the joint WHO/Africa CDC $518 million response plan, the $38 million in additional U.S. funding, and CEPI's fast-tracking of three vaccine candidates (Moderna, Oxford, and IAVI) with over $60 million in funding. It also captures the political fallout and violent quarantine facility protests in Nanyuki, Kenya. 2. **New Finding (`ivonescimab-harmoni-6-lung-cancer-os-win`)**: * Documented the landmark results of the Phase 3 HARMONi-6 trial presented at ASCO 2026, where the first-in-class PD-1xVEGF bispecific antibody **ivonescimab** (AK112) plus chemotherapy slashed the risk of death by **34%** (median OS of 27.9 months vs. 23.7 months) in first-line advanced squamous lung cancer. The note highlights these survival gains alongside critical caveats regarding global applicability, lack of benefit in older populations ($\ge$65), and the need for global phase 3 trial validation. 3. **New Finding (`grail-nhs-galleri-mced-trial-results`)**: * Captured the full results of the NHS-Galleri trial presented at ASCO 2026. While the trial missed its primary endpoint (reducing combined Stage III and IV cancers over 3 years due to a first-round detection "bump"), it demonstrated a substantial **26% reduction** in Stage IV diagnoses by the third round, preserved a high specificity of 99.55%, and maintained a strong positive predictive value (52.0%). The note outlines these findings along with public health critiques regarding NHS diagnostic resource constraints. 4. **New Finding (`innovent-cldn182-adc-gastric-cancer-phase3`)**: * Reported on Innovent Biologics' Phase 3 MarsLight-11 win for **IBI343** (arcotatug tavatecan), the world's first CLDN18.2-targeted ADC to achieve a Phase 3 victory and enter regulatory review (accepted for priority review by China's NMPA). The note details the trial's design, its exatecan mechanism of action, and the commercial significance of Innovent's $1.2 billion partnership with Takeda. 5. **Forward-Looking Watches**: * Registered four ongoing and one-shot watches to track critical upcoming catalysts: * Phase 1 clinical trial readouts for the fast-tracked Bundibugyo Ebola vaccine candidates. * Global Phase 3 trial readouts for ivonescimab (HARMONi-3 and HARMONi-7). * NMPA's regulatory decision on IBI343 in China (priority review). * The release of long-term cancer-specific mortality data from the NHS-Galleri trial.